Page 4 - Fabrice Andre News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adjuvant palbociclib combined with endocrine therapy failed to extend invasive DFS compared with endocrine therapy alone among patients with stage IIA hormone receptor-positive, HER2-negative breast cancer, according to study results.The findings, presented during an ASCO Plenary Series session, also showed the addition of the cyclin-dependent kinase (CDK)4/6 inhibitor did not improve other

Prepare for a significant change in early cancer detection that will impact nearly every stage of cancer diagnosis and treatment. Cancer doctors, care providers

A recent study by Pathfinder revealed that even a simple blood test can detect multiple cancer types in a patient even before there are any obvious symptoms of illness. The study was offered to over 6,000 adults aged 50 or older and detected few cases of illness. The overall results revealed that nearly a third of the cancer tests were for cancer, which was not regularly checked or was in the early stages.

But results of genomic testing need to be interpreted carefully. An alteration-drug match not supported by clinical trial evidence has no benefit for patients.

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting News provided by Share this article Share this article INDIANAPOLIS, May 19, 2021 /PRNewswire/ -- New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio ® (abemaciclib) from the Phase 3 monarchE trial in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ear...